Best Stocks Under $20 Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $20.00 (20 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Show:
Harmonic stock logo

#1 - Harmonic

NASDAQ:HLIT
Stock Price:
$9.58 (-$0.12)
P/E Ratio:
13.49
Market Cap:
$1.07 billion
Average Trading Volume:
1.94 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$17.20 (79.5% Upside)
Harmonic Inc., together with its subsidiaries, provides broadband solutions worldwide. The company operates through Broadband and Video segments. The Broadband segment sells broadband access solutions and related services, including cOS software-based broadband access solutions to broadband operators; and cOS central cloud services, a subscription service for cOS customers. The Video segment sells video processing, production, and playout solutions and services to cable operators, and satellite and telco Pay-TV service providers, as well as to broadcast and media, including streaming media companies. Its video processing appliance solutions include network management and application software, and hardware products, such as encoders, video servers, high-density stream processing systems, and edge processors. This segment also provides VOS360 SaaS platform that provides both streaming and channel origination and distribution services; and software-as-a-service (SaaS) solutions, which enables the packaging and delivery of streaming services, including live streaming, VOD, catch-up TV, start-over TV, network-DVR and cloud-DVR services through HTTP streaming to various device along with dynamic and personal ad insertion. The company also provides technical support and professional services, such as maintenance and support, consulting, implementation, integration services, program management, technical design and planning, building and site preparation, integration and equipment installation, end-to-end system testing, and training, as well as SaaS-related support and deployment. It sells its products through its direct sales force, as well as through independent resellers and systems integrators. The company was incorporated in 1988 and is headquartered in San Jose, California.
Clean Energy Fuels stock logo

#2 - Clean Energy Fuels

NASDAQ:CLNE
Stock Price:
$2.31 (+$0.10)
P/E Ratio:
-5.25
Market Cap:
$515.73 million
Average Trading Volume:
1.65 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$5.60 (142.4% Upside)
Clean Energy Fuels Corp. provides natural gas as alternative fuels for vehicle fleets and related fueling solutions in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains vehicle fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.
DigitalBridge Group stock logo

#3 - DigitalBridge Group

NYSE:DBRG
Stock Price:
$17.42 (+$0.28)
P/E Ratio:
35.55
Market Cap:
$2.85 billion
Average Trading Volume:
2.02 million shares
Dividend Yield:
0.23%
<
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$22.08 (26.8% Upside)
DigitalBridge is an infrastructure investment firm specializing in digital infrastructure assets. They provide services to institutional investors. They primarily invest in data centers, cell towers, fiber networks, small cells, and edge infrastructure. DigitalBridge Group, Inc. was founded in 1991 and is headquartered in Boca Raton, Florida with additional offices in Los Angles, California, and New York New York.
Zura Bio stock logo

#4 - Zura Bio

NASDAQ:ZURA
Stock Price:
$3.48 (+$0.17)
Market Cap:
$149.95 million
Average Trading Volume:
271,105 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$16.40 (371.3% Upside)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Quanterix stock logo

#5 - Quanterix

NASDAQ:QTRX
Stock Price:
$16.10 (-$0.20)
P/E Ratio:
-18.72
Market Cap:
$615.83 million
Average Trading Volume:
347,587 shares
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$32.00 (98.8% Upside)
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Scholar Rock stock logo

#6 - Scholar Rock

NASDAQ:SRRK
Stock Price:
$14.79 (+$0.79)
P/E Ratio:
-7.43
Market Cap:
$1.15 billion
Average Trading Volume:
781,279 shares
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$25.17 (70.2% Upside)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Kimbell Royalty Partners stock logo

#7 - Kimbell Royalty Partners

NYSE:KRP
Stock Price:
$16.00 (+$0.12)
P/E Ratio:
17.39
Market Cap:
$1.52 billion
Average Trading Volume:
344,228 shares
Dividend Yield:
10.69%
<
Consensus Rating:
Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$21.00 (31.3% Upside)
Kimbell Royalty Partners, LP, together with its subsidiaries, engages in acquiring and owning mineral and royalty interests in oil and natural gas properties in the United States. It serves as the general partner of the company. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Ardelyx stock logo

#8 - Ardelyx

NASDAQ:ARDX
Stock Price:
$6.39 (-$0.12)
P/E Ratio:
-21.30
Market Cap:
$1.49 billion
Average Trading Volume:
6.08 million shares
Consensus Rating:
Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$12.69 (98.6% Upside)
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARC Resources stock logo

#9 - ARC Resources

OTCMKTS:AETUF
Stock Price:
$18.51 (+$0.33)
P/E Ratio:
9.54
Market Cap:
$11.06 billion
Average Trading Volume:
116,711 shares
Dividend Yield:
1.39%
<
Consensus Rating:
Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$21.92 (18.4% Upside)
ARC Resources Ltd. engages in the acquiring and developing crude oil, natural gas, condensate, and natural gas liquids in Canada. It primarily holds interests in the Montney basin located in Alberta and northeast British Columbia. ARC Resources Ltd. was founded in 1996 and is based in Calgary, Canada.
Integra Resources stock logo

#10 - Integra Resources

NYSEAMERICAN:ITRG
Stock Price:
$0.85 (+$0.02)
P/E Ratio:
-1.57
Market Cap:
$74.78 million
Average Trading Volume:
135,753 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$3.75 (343.6% Upside)
Integra Resources Corp., a precious metals exploration and development company, engages in the acquisition, exploration, and development of mineral properties in the Great Basin of the Western United States. The company explores for gold and silver deposits. It primarily focuses on developing DeLamar Project located in southwestern Idaho; and the Wildcat and Mountain View Projects located in western Nevada. It also holds a portfolio of early-stage exploration projects in Idaho, Nevada, and Arizona. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.
Triple Flag Precious Metals stock logo

#11 - Triple Flag Precious Metals

NYSE:TFPM
Stock Price:
$15.74 (+$0.67)
P/E Ratio:
82.85
Market Cap:
$3.16 billion
Average Trading Volume:
158,776 shares
Dividend Yield:
1.35%
<
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$17.25 (9.6% Upside)
Triple Flag Precious Metals Corp., a precious-metals-focused streaming and royalty company, engages in acquiring and managing precious metals, streams, royalties and other mineral interests in Australia, Canada, Colombia, Cote d'Ivoire, Honduras, Mexico, Mongolia, Peru, South Africa, the United States, and internationally. The company has a portfolio of streams and royalties providing exposure to gold, silver, nickel, copper, zinc, and lead. It holds a royalty interest in the Beta Hunt mine located in Pert, Wester Australia; the Camino Rojo gold and silver mine located in Mexico; the El Mochito polymetallic mine located in north-western Honduras; and La Colorada polymetallic mine located in Mexico. Triple Flag Precious Metals Corp. was founded in 2016 and is based in Toronto, Canada.
Larimar Therapeutics stock logo

#12 - Larimar Therapeutics

NASDAQ:LRMR
Stock Price:
$6.46 (+$0.06)
P/E Ratio:
-7.60
Market Cap:
$412.15 million
Average Trading Volume:
561,751 shares
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$18.50 (186.4% Upside)
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Grab stock logo

#13 - Grab

NASDAQ:GRAB
Stock Price:
$3.51 (+$0.16)
P/E Ratio:
-35.10
Market Cap:
$13.77 billion
Average Trading Volume:
24.49 million shares
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$5.10 (45.3% Upside)
Grab Holdings Limited engages in the provision of superapps in Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. The company offers its Grab ecosystem, a single platform with superapps for driver- and merchant-partners and consumers, that allows access to mobility, delivery, digital financial services, and enterprise sector offerings. The company is headquartered in Singapore.
Uranium Energy stock logo

#14 - Uranium Energy

NYSEAMERICAN:UEC
Stock Price:
$6.73 (+$0.06)
P/E Ratio:
-672.50
Market Cap:
$2.72 billion
Average Trading Volume:
7.89 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$8.80 (30.9% Upside)
Uranium Energy Corp., together with its subsidiaries, engages in exploration, pre-extraction, extraction, and processing uranium and titanium concentrates in the United States, Canada, and Paraguay. It owns interests in the Palangana mine, Goliad, Burke Hollow, Longhorn, and Salvo projects located in Texas; Anderson, Workman Creek, and Los Cuatros projects situated in Arizona; Dalton Pass and C de Baca project located in New Mexico; Roughrider, Shea Creek, Christie Lake, Horseshoe-Raven, Hidden Bay, Diabase, West Bear, JCU, and other project located in Canada; and Yuty, Oviedo, and Alto Paraná titanium projects in Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. Uranium Energy Corp. was incorporated in 2003 and is headquartered in Corpus Christi, Texas.
Aspen Aerogels stock logo

#15 - Aspen Aerogels

NYSE:ASPN
Stock Price:
$16.63 (+$1.45)
P/E Ratio:
-25.20
Market Cap:
$1.28 billion
Average Trading Volume:
967,910 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$19.00 (14.3% Upside)
Aspen Aerogels, Inc. designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier. The company offers PyroThin thermal barriers for use in lithium-ion batteries in electric vehicles and energy storage industries; Pyrogel XTE that reduces the risk of corrosion under insulation in energy infrastructure operating systems; and Pyrogel HPS for applications within the power generation market. It also offers Pyrogel XTF to provide protection against fire; Cryogel Z for sub-ambient and cryogenic applications in the energy infrastructure market; Spaceloft Subsea for use in pipe-in-pipe applications in offshore oil production; and Cryogel X201, which is used in designing cold systems, such as refrigerated appliances, cold storage equipment, and aerospace systems. The company was founded in 2001 and is headquartered in Northborough, Massachusetts.
Rani Therapeutics stock logo

#16 - Rani Therapeutics

NASDAQ:RANI
Stock Price:
$6.69 (+$0.02)
P/E Ratio:
-5.03
Market Cap:
$335.57 million
Average Trading Volume:
120,163 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$11.50 (71.9% Upside)
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Gibson Energy stock logo

#17 - Gibson Energy

OTCMKTS:GBNXF
Stock Price:
$16.68 (+$0.56)
P/E Ratio:
16.04
Market Cap:
$2.70 billion
Average Trading Volume:
28,801 shares
Dividend Yield:
7.14%
<
Consensus Rating:
Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$23.80 (42.7% Upside)
Gibson Energy Inc., together with its subsidiaries, engages in the gathering, storage, optimization, processing, and marketing of liquids and refined products in Canada and the United States. It operates through Infrastructure and Marketing segments. The Infrastructure segment operates a network of liquid infrastructure assets that include oil terminals, rail loading and unloading facilities, gathering pipelines, a crude oil processing facility, and other terminals. The Marketing segment purchases, sells, stores, and optimizes hydrocarbon products, including crude oil, natural gas liquids, road asphalt, roofing flux, frac oils, light and heavy straight run distillates, vacuum gas oil, and an oil-based mud product. It serves producers, refiners, marketers, and integrated companies, as well as exploration and production companies. The company was formerly known as Gibson Energy Holdings ULC and changed its name to Gibson Energy Inc. in April 2011. Gibson Energy Inc. was founded in 1953 and is headquartered in Calgary, Canada.
Actinium Pharmaceuticals stock logo

#18 - Actinium Pharmaceuticals

NYSEAMERICAN:ATNM
Stock Price:
$6.96 (-$0.21)
P/E Ratio:
-3.80
Market Cap:
$204.62 million
Average Trading Volume:
326,799 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$25.72 (269.5% Upside)
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.
Alpine Income Property Trust stock logo

#19 - Alpine Income Property Trust

NYSE:PINE
Stock Price:
$15.42 (+$0.13)
P/E Ratio:
-385.50
Market Cap:
$210.02 million
Average Trading Volume:
54,407 shares
Dividend Yield:
7.40%
<
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$18.35 (19.0% Upside)
Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that seeks to deliver attractive risk-adjusted returns and dependable cash dividends by investing in, owning and operating a portfolio of single tenant net leased properties that are predominately leased to high-quality publicly traded and credit-rated tenants.
Bitdeer Technologies Group stock logo

#20 - Bitdeer Technologies Group

NASDAQ:BTDR
Stock Price:
$6.71 (+$0.06)
P/E Ratio:
-15.98
Market Cap:
$751.32 million
Average Trading Volume:
1.76 million shares
Consensus Rating:
Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$13.64 (103.3% Upside)
Bitdeer Technologies Group operates as a technology company for the cryptocurrency mining community. It mines cryptocurrencies for its own account and serve the cryptocurrency mining community by providing cryptocurrency mining solution. The company handles various processes involved in mining, such as miner procurement, transport logistics, mining datacenter design and construction, mining machine management, and daily operations. It has mining datacenters deployed in the United States and Norway. The company is headquartered in Singapore.
Sutro Biopharma stock logo

#21 - Sutro Biopharma

NASDAQ:STRO
Stock Price:
$3.72 (-$0.05)
P/E Ratio:
-2.09
Market Cap:
$232.28 million
Average Trading Volume:
998,375 shares
Consensus Rating:
Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$12.57 (237.9% Upside)
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
MAG Silver stock logo

#22 - MAG Silver

NYSEAMERICAN:MAG
Stock Price:
$12.16 (+$0.31)
P/E Ratio:
25.86
Market Cap:
$1.25 billion
Average Trading Volume:
860,320 shares
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$18.00 (48.1% Upside)
MAG Silver Corp. develops and explores for precious metal properties in Canada. It explores for silver, gold, lead, copper, and zinc deposits. The company's flagship property is the 44% owned Juanicipio property located in the Fresnillo District, Zacatecas State, Mexico. MAG Silver Corp. is headquartered in Vancouver, Canada.
TAL Education Group stock logo

#23 - TAL Education Group

NYSE:TAL
Stock Price:
$12.19 (+$0.24)
P/E Ratio:
-110.82
Market Cap:
$7.77 billion
Average Trading Volume:
7.00 million shares
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$12.37 (1.4% Upside)
TAL Education Group provides K-12 after-school tutoring services in the People's Republic of China. The company offers tutoring services to K-12 students covering various academic subjects, including mathematics, physics, chemistry, biology, history, geography, political science, English, and Chinese. It provides tutoring services primarily through small-class services under the Xueersi, Xueersi Online School, First Leap, Tipaipai, Xiaohou AI, Xiaohoucode, Aiqidao, Mamabang, Kaoyanbang, and Shunshunliuxue brand names; and personalized premium services under Izhikang name. The company also operates jzb.com, an online education platform; provides investment management and consulting services; develops and sells software and networks, as well as related consulting services; and sells educational materials and products. TAL Education Group was founded in 2003 and is headquartered in Beijing, the People's Republic of China.
SunOpta stock logo

#24 - SunOpta

NASDAQ:STKL
Stock Price:
$6.55 (+$0.19)
P/E Ratio:
-4.28
Market Cap:
$774.87 million
Average Trading Volume:
819,094 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$9.40 (43.5% Upside)
SunOpta Inc. engages in manufacture and sale of plant-based and fruit-based food and beverage products in the United States, Canada, and internationally. The company provides plant-based beverages utilizing oat, almond, soy, coconut, rice, hemp, and other bases under the Dream and West Life brands; oat-based creamers under the SOWN brand; ready-to-drink protein shakes; and nut, grain, seed, and legume based beverages; packaged teas and concentrates; and meat and vegetable broths and stocks. It also offers plant-based ingredients, such as oatbase, oatgold, soybase, hempbase, and soypowders and okara; ready-to-eat fruit snacks made from apple purée and juice concentrate in bar, bit, twist, strip and sandwich formats; cold pressed fruit bars; liquid and powder ingredients utilizing oat, soy and hemp bases; ready-to-eat fruit smoothie and chia bowls topped with frozen fruit; consumer products, which includes protein shakes, teas, broths, and fruit snacks; and liquid and dry ingredients for internal use and for sale to other food and beverage manufacturers. It sells its products through various distribution channels including private label products to retail customers; branded products under co-manufacturing agreements to other branded food companies for their distribution; and its own branded products to retail and foodservice customers. The company was formerly known as Stake Technology Ltd. and changed its name to SunOpta Inc. in October 2003. SunOpta Inc. was incorporated in 1973 and is headquartered in Eden Prairie, Minnesota.
Canadian Western Bank stock logo

#25 - Canadian Western Bank

OTCMKTS:CBWBF
Stock Price:
$19.71 (+$0.37)
P/E Ratio:
7.30
Average Trading Volume:
6,644 shares
Dividend Yield:
3.60%
<
Consensus Rating:
Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$36.57 (85.5% Upside)
Canadian Western Bank provides personal and business banking products and services in Western Canada. The company offers current, savings, US dollar, chequing, flex notice, organization, business trust, and trust fund investment accounts. It also offers commercial lending and real estate, equipment financing and leasing, aviation financing, and dealership financing products; agriculture lending products and AgriInvest savings account; variable and fixed rate mortgages; line of credit; registered retirement savings plan, consolidation, and vehicle loans; and credit cards. In addition, the company offers cash management services; prestige banking services; life and disability creditor insurance products; and ATM, mobile, and online banking services, as well as cheque order services. Further, it provides investment products comprising guaranteed investment certificates, US dollars investments plans, registered retirement income fund, tax free savings accounts, registered education savings plans, and mutual funds; financial planning services; and specialized financing, wealth management, and trust services. Canadian Western Bank was founded in 1984 and is headquartered in Edmonton, Canada.

More Stock Ideas from MarketBeat